Fractional Erbium YAG Laser vs Intradermal and Systemic Tranexamic Acid
Fractional Erbium YAG Laser vs Intradermal and Systemic Tranexamic Acid in Combination With Topical Hydroquinone for Refractory Melasma
Egymedicalpedia
45 participants
Jun 1, 2024
INTERVENTIONAL
Conditions
Summary
Melasma is a common acquired disorder of hyperpigmentaion caused by increased melanin production by melanocytes. Melasma is a name derived from the Greek word melas meaning black.It is characterized by the appearance of brownish or grayish symmetrical patches on sun-exposed skin, most commonly on the face. Compared to men, women are more likely to be affected.
Eligibility
Inclusion Criteria1
- \- Patients of both sexes with melasma.
Exclusion Criteria4
- Pregnancy
- Lactation
- Administration of oral contraceptive pills or any phototoxic drug within 1 month prior to study
- Patients with a history of thrombosis, abnormal bleeding profile, known hypersensitivity to TA or HQ, and endocrinal disease.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
to evaluate and compare efficacy of: * Fractional Er: YAG laser combined with topical hydroquinone. * Intradermal injection of tranexamic acid combined with topical hydroquinone cream. * Oral administration of tranexamic acid combined with topical hydroquinone cream. In treating refractory melasma.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06522984